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Conclusion: Reduced-RADPLAT for HPC achieved comparative survival and local control rates 
with lower toxicities compared with concurrent chemoradiotherapies including original RADPLAT. 
S-1 adjuvant chemotherapy showed a survival benefit. 
Obejectives: To evaluate the efficacy and toxicities of targeted intra-arterial (IA) infusion of 
cisplatin with concurrent radiotherapy with a reduced dose (reduced-RADPLAT) for resectable 
hypopharyngeal cancer (HPC). 
Methods: Between 1999 and 2012, 50 patients with stage II to IVA HPC primarily treated by 
reduced-RADPLAT were analyzed. They were treated by 2-5 courses of IA cisplatin infusion (100 
mg per body) with simultaneous systemic infusion of sodium thiosulfate concurrent with 
conventional radiotherapy (66-70 Gy). After 2003, S-1, an oral fluoropyrimidine, adjuvant 
chemotherapy were administered to all eligible patients. 
Results: During a median follow-up of 48.6 months, the estimated 3- and 5-year overall survival 
(OS), progression-free survival (PFS), local control, locoregional control, and laryngoesophageal 
dysfunction-free survival (LEDFS) rates were 76.0 and 62.0%, 58.0 and 50.0%, 72.0 and 70.0%, 
66.0 and 62.0%, and 56.0% and 54.0%, respectably. Grade 3 toxicities were observed in 30.0%. No 
patient had grade 4 or severer toxicities. No patient required tube feeding or tracheotomy at 3 
months after treatment. T4-lesions and S-1 administration were significant factors predicting poor 
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and good OS, PFS, and LEDFS, respectively. 
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     Hypopharyngeal cancer (HPC) carries one of the worst prognoses in squamous cell carcinoma 
of the head and neck (SCCHN), and is mostly diagnosed at an advanced stage requiring combined 
therapies.[1,2] For a long time, surgery followed by postoperative irradiation had been treatment of 
choice. A prospective randomized phase 3 study conducted by the European Organization for 
Research and Treatment of Cancer, the EORTC 24891 study, compared larynx-preserving (induction 
chemotherapy plus definitive radiation therapy in patients showing a complete response or surgery in 
those without a response) with conventional (total laryngectomy with partial pharyngectomy and 
postoperative radiotherapy) treatment in selected cases of advanced pyriform sinus carcinoma.[1] 
The results showed that the larynx-preserving treatment did not compromise either disease control or 
survival compared with conventional treatment. Individual patient data meta-analysis showed that 
the benefit of concurrent chemoradiotherapy was significantly greater than that of induction or 
adjuvant chemotherapy for non-metastatic head and neck cancer patients.[3,4] In sub-group analyses, 
the benefit of concurrent chemoradiotherapy for HPC was also confirmed.[3,4] 
An alternative chemoradiation protocol involves 4 cycles of targeted intra-arterial (IA) 
infusion of high-dose (150 mg/m2) cisplatin with concurrent radiotherapy (RADPLAT).[5] 
Simultaneous with each IA infusion, the neutralizing agent of cisplatin, sodium thiosulfate, is infused 
into the systemic circulation, allowing cisplatin administration at a level that is at least 6 times 
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higher than in the standard intravenous chemotherapy protocol, concurrent chemoradiotherapy 
(CCRT) protocol of the RTOG 91-11 study,[6] over a relatively short interval. 
We previously evaluated the efficacy of a reduced-RADPLAT protocol in candidates for total 
laryngectomy.[7,8] The patients were treated with 2 or 3 cycles of a fixed dose of cisplatin IA 
infusion (100 mg per body) during 66-Gy irradiation. The protocol for resectable laryngeal 
carcinoma could achieve similar local control and survival to the standard CCRT protocol in the 
RTOG 91-11 study, but with lower toxicities.[7,8] Also, adjuvant chemotherapy with S-1, an oral 
fluoropyrimidine, following reduced-RADPLAT was an effective treatment option to control distant 
metastases for resectable laryngeal cancer.[7] 
In the literature, there are only a few reports on the efficacy of IA chemotherapy (IAC) 
concomitant with radiotherapy for HPC.[9,10] Here, we retrospectively evaluated the efficacy and 
feasibility of our protocol, reduced-RADPLAT, for resectable HPC.               
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MATERIALS AND METHODS 
Patients and Treatment Protocol 
     All patients had histologically proven HPC with clinical stage II to IVA disease using the 
staging system of the Union Internationale Contre le Cancer[11] without evidence of other 
malignancies and distant metastases at diagnosis, the surgical treatment of which requires total or 
partial laryngopharyngectomy with reconstructive surgery using a conventional free flap, such as 
from the forearm or jejunum.  
Pretreatment staging, involving laryngoscopy and high-resolution computed tomography (CT) 
scanning of the primary tumor and neck, was performed before primary treatment. To rule out 
synchronous primary cancers, we performed CT of the chest, gastrointestinal fiberscopy, or positron 
emission tomography. Before starting therapy, all patients signed a letter of informed consent 
approved by our Institutional Review Boards (No. 5428).  
All patients were treated primarily with reduced-RADPLAT, as described previously.[7] 
Briefly, all patients received irradiation by conventional once-a-day, 2 Gy-per-fraction regimen to a 
cumulative dose of 66-70 Gy. They were treated with 2 courses of IA cisplatin infusion (100 mg per 
body) during 40-Gy irradiation. An additional cisplatin dose (50 mg per body) was given by IA 
infusion to lymph nodes larger than 3 cm. Tumor responses were evaluated by endoscopy and CT. 
Patients who showed marked tumor reduction (more than 80%) received sequential irradiation 
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(26-30 Gy). Patients with clear residual disease (less than 80% reduction) received a third to fifth 
course of IA cisplatin during sequential irradiation (26-30 Gy).  
Acute toxicity was assessed weekly, including a blood cell count, serum chemistry profile, and 
mucositis, during chemoradiotherapy. Toxicity assessments were based on Common Terminology 
Criteria for adverse Events version 3.0. 
All patients were examined by endoscopic, CT, and/or magnetic resonance imaging 4 weeks 
after reduced-RADPLAT completion to evaluate their response. 
 
Eligibility Criteria and Treatment Schedule of S-1 Adjuvant Chemotherapy 
     Before 2003, none of the patients received S-1 adjuvant chemotherapy. In the 
reduce-RADPLAT protocol, sodium thiosulfate is administered as a neutralizing agent for cisplatin 
to reduce toxicities; thus, the effect of cisplatin and irradiation to micro metastases at distant sites is 
not expected. Therefore, we administered S-1 to all eligible patients to receive the adjuvant 
chemotherapy within 3 months after reduced-RADPLAT after 2003. Only patients who achieved CR 
at the primary site were eligible for S-1 adjuvant chemotherapy. The S-1 dosage was selected as 
follows: for patients: with a body surface area (BSA) of less than 1.25 m2, 60 mg per day; with a 
BSA of at least 1.25 m2 but less than 1.5 m2, 80 mg per day; with a BSA of at least 1.5, 100 mg per 
day. S-1 was administered for 2 weeks followed by 1 week rest for 1 year. Other detailed eligibility 
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criteria and the treatment protocol of S-1 adjuvant chemotherapy were described previously.[7,12]  
 
Follow-Up 
All patients were followed for relapse every month for 2 years, every 3 months for at least 
another 3 years, and every 6 months thereafter. Patients with evidence of pathological residual 
disease at the primary site were recommended to undergo salvage surgery. Neck dissection was 




     Overall survival (OS), progression-free survival (PFS), local control (LC), locoregional 
control (LRC), and laryngoesophageal dysfunction-free survival (LEDFS) rates were analyzed with 
Kaplan-Meier methods. Survival and control periods were defined as the period between the start of 
the reduced-RADPLAT treatment and events. Events for LEDFS included death, local relapse, total 
or partial laryngectomy, tracheotomy at 2 years or later, or feeding tube use at 2 years or later.[13] 
Clinical characteristics were analyzed for their association with OS, PFS, LC, LRC, and LEDFS 
using the Cox-proportional hazards model. Predictive variables with p-values lower than 0.10 for the 
univariate Cox-proportional hazards model were included in a multivariate model and significance 
11 
 
of 0.05 was used to determine independent factors. The significance of differences in the 
cisplatin-dose between T1-3 and T4 tumors was assessed using the Mann-Whitney U test. All 





Between January 1999 and September 2012, 111 patients of squamous cell carcinoma of the 
hypopharynx were treated at the Division of Otolaryngology-Head and Neck Surgery, Kanazawa 
University Hospital. Among them, 51 patients were treated with reduced-RADPLAT protocol. One 
patient was excluded from the analyses because the primary tumor invaded the carotid artery, being 
classified as unresectable. Thus, we analyzed 48 patients in total, and their detailed characteristics 
and clinical courses are summarized in Table 1 and Fig. 1, respectively. All surviving patients had a 
minimum follow-up of 36 months (range, 0 to 154; median, 48.6). 
 
Cycles and Infusion Arteries for reduced-RADPLAT 
     Four patients (8.0%) discontinued reduced-RADPLAT, to whom only 1 cycle of IAC was 
administered, for the following reasons: progressive anemia due to hereditary spherocytosis, 
advanced rectal cancer, allergic reaction to contrast medium, and patient refusal (Supplementary 
Table 1). Two patients underwent surgery after 2 courses of IAC plus 40-Gy irradiation. Patients 
were considered to have completed the course of treatment if administered at least 2 cycles of IAC 
and a 100% dose of radiation. A total of 47 patients (94.0%) completed radiation therapy, and 44 
patients (88.0%) completed treatment. Details of the number of infusion arteries are summarized in 
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Supplementary Table 2. Twenty-one patients (42.0%) with a local tumor crossing the midline 
required bilateral infusions. In addition, 13 patients (26.0%) with N2b (n = 10), N2c (n =2), and N3 
(n = 1) received IA infusions for neck lesions. The superior thyroid artery was the most frequently 
used for IA cisplatin infusion, and the occipital artery for neck lesions (Supplementary Table 3). 
Cisplatin doses in total and for primary tumors are listed in Supplementary Table 4. Total amounts of 
cisplatin were similar between T1-3 (297.8 ± 147.2) and T4 (355.0 ±179.1) diseases (p = 0.218), 
in contrast, the dose of cisplatin infused for a primary tumor was significantly higher in T4 (333.0 
± 159.9) than T1-3 (252.0 ± 92.2) primary lesions ( p = 0.016). 
 
Treatment Outcome 
     CR at both primary and regional sites was achieved in 44 patients (88.0%), a partial response 
(PR) in the neck with CR at the primary site in 1 patient (2.0%), and PR at both the primary site and 
neck in 5 patients (10.0%). The initial recurrent sites were the hypopharynx in 10, regional lymph 
nodes in 5, and distant sites in 5 (Fig. 1). Four patients were salvaged with surgery, however, other 
patients rejected salvage surgery or were not resectable because of invasions to carotid artery or 
prevertebral fascia. 
     Until July 2015, 27 patients (54.0%) were alive, and 25 of the 27 remained cancer-free. Six, 5, 
and 7 died of local recurrence, distant metastases, and unrelated causes, respectively. Among the 7 
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patients who died of unrelated causes, four had T4 disease: two cases of malignancy at other sites 
(bladder and esophagus), one of aspiration pneumonia, and of deep neck infection. 
The OS and PFS curves are shown in Fig. 2. The estimated 3- and 5-year OS and PFS rates 
were 76.0 and 62.0%, and 58.0 and 50.0%, respectively. The LC, LRC, and LEDFS curves are 
shown in Fig. 3. The estimated 3- and 5-year LC, LRC, and LEDFS rates were 72.0 and 70.0%, 66.0 
and 62.0%, and 56.0 and 54.0%, respectively. 
 
Factors involved in OS, PFS, LC, LRC, and LEDFS 
     In multivariate analysis, both the T-status and S-1 administration remained as independent 
predictive factors for OS and PFS, respectively (Tables 2, 3). No clinical factor had a significant 
impact on LC and LRC (Supplementary Tables 5, 6). In multivariate analysis, the T-status and S-1 
administration remained as independent factors to predict LEDFS (Table 4). 
 
Toxicity 
     The occurrence and incidence of hematological and non-hematological toxicities of grade 3 or 
higher with reduced-RADPLAT are summarized in Table 5. No patient had catheter-related central 
nerovous system problems or peripheral neuropathy. There was a case of grade 3 thyrotoxicosis 
during the second cycle of cisplatin infusion into the superior thyroid artery. The patient completed 
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radiation therapy, but no additional cycle of IAC was administered. No patient required tube feeding 
at 3 months after reduced-RADPLAT completion, except for five patients rquiring feeding by 
gastrostomy tube after local recurrence. Seven patients required tracheotomy after 
reduced-RADPLAT for the following reasons: local recurrence (4 patients), temporary airway 
obstruction after neck dissection (1 patient), deep neck infection (1 patient), and recurrent laryngeal 




Although larynx-preserving approaches are assessed mainly in patients with laryngeal cancer, 
no single randomized phase 3 study has specifically addressed the role of concomitant 
chemoradiotherapy in HPC management. Therefore, a standard concomitant chemoradiotherapy 
protocol for HPC has not yet been established. 
Caudell et al. reported that, in their study of advanced laryngeal and hypopharyngeal cancer, 
OS, PFS, LRC, and LEDFS at 3 years were 55.8, 64.6, 71.8, and 32.2%, respectively.[13] In the 
induction chemotherapy, with docetaxel, cisplatin, and 5-fluorouracil, followed by radiotherapy with 
or without additional chemotherapy, Pointreau et al. showed in resectable laryngeal and 
hypopharyngeal cancers, that OS, and disease-free survival at 3 years were 60 and 58%, 
respectively.[14] Samant et al. reported the efficacy and toxicities of RADPLAT in 25 pyriform sinus 
carcinoma patients.[10] The CR rate, and estimates of OS and LRC at 5 years were 92, 23, and 88%, 
respectively. The overall incidence of grade 3 or 4 toxicity was 40% in their series. One third of the 
patients alive with organ preservation were not able to swallow without depending on the feeding 
tube. In contrast, toxicities of grade 3 or more were observed only in 30% of patients in our study. 
Furthermore, no tracheotomy or gastrostomy was performed as late toxicities of reduced-RADPLAT 
in our study. Thus, our reduced-RADPLAT protocol achieved survival and LC rates comparable with 
the original RADPLAT protocol for pyriform sinus carcinomas, with lower toxicities. 
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The EORTC 24891 study showed a significant difference in the rate of distant metastases as 
the first failure between the immediate surgery (36%) and induction chemotherapy (25%) arms, and 
established the efficacy of chemotherapy for distant metastases in HPC.[1] However, in the 
RADPLAT protocol, sodium thiosulfate is administered as a neutralizing agent for cisplatin to 
reduce the toxicities; thus, the efficacy of cisplatin and irradiation to micro-metastases at distant sites 
is not expected. From some reports of RADPLAT for HPC, distant metastasis rates were from 14 to 
40%.[9,10,15] In the current study, only 5 of 50 patients (10.0%) developed distant metastases, 
which is the lowest among reported studies. A phase 3 randomized study to evaluate S-1, the current 
generation of oral fuluoropyrimidine, compared with UFT, the previous generation of oral 
fluoropyrimidine, as a control in patients after curative therapy was conducted for advanced 
SCCHN.[16,17] In the study, S-1 significantly improved OS compared with UFT, one reason for 
which was the lower incidence of distant recurrence in the S-1 than UFT group, most likely 
contributing to better survival in the S-1 group. For advanced HPC with CR following 
reduced-RADPLAT, although statistical analysis was not performed because only 5 cases had distant 
metastases, S-1 adjuvant chemotherapy might have contributed to the low distant metastases rate, 
which resulted in better survivals, such as OS, PFS, and LEDFS rates as shown in our study. 
Doweck et al. reported that the tumor volume was the most important factor predictive of the 
treatment outcome among advanced SCCHN patients in the RADPLAT study.[18] However, in the 
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current study, no difference in LC and LRC between patients presenting with T1-3 and T4 diseases 
was observed. We speculate that, for resectable HPC, the primary tumor volume is not a significant 
predictive factor to select patients for reduced-RADPLAT. Therefore, larger tumors, such as 
unresectable primary diseases, require an increased dose of cisplatin as in the RADPLAT regimen; 
however, reduced-dose cisplatin would be satisfactory to control moderately large tumors, such as 
resectable HPC, independent of the T-status.[7,8,19] In contrast, LEDFS was significantly poorer in 
T4 than in T1-3 diseases. The cause of the poorer LEDFS in T4 disease is at least in part because of 
death from other diseases. Total doses of cisplatin are similar between T1-3 and T4 lesions, but the 
amount of cisplatin infused into primary diseases is significantly greater in T4 than T1-3 lesions. The 
damage to local organs might be more severe in T4 cases, resulting in a higher mortality because of 
local dysfunction such as aspiration pneumonia and compromised resistance to infection. For the 
same reason, the other survival analyses, OS and PFS, also showed significantly poorer rates in T4 
compared with T1-3 patients. The cause of higher mortality due to other diseases in T4 patients 
should be elucidated in future analyses. 
In this study, tumor laterality (tumor does/does not extend across the midline) and number of 
infused arteries were not significant predictive factors of LC and LRC, respectively. Rasch et al., in 
the IAC arm of the comparative multi-institutional study between intravenous versus intra-arterial 
chemoradiotherapy, reported that better survival was associated with tumors not extending across the 
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midline: uni- or bilateral infusion was an important predictive factor.[20] In their study, patients were 
treated at five institutions with experience of at least five procedures before entering the trial, and 
neurological toxicities > grade 2 were observed in 6.7% patients. However, no catheter-related 
complication was observed in our single institutional setting. We speculate that the laterality and 
number of infused arteries are not significant predictive factors for LC and LRC if feeding arteries 
are correctly selected and resectable primary tumors are fully infused with cisplatin at an 
experienced institution.  
In conclusion, reduced-RADPLAT for HPC achieved comparative survival and local control 
rates with lower toxicities compared with other chemoradiotherapy protocol including previous 
RADPLAT treatment. Although the study design was retrospective and the conclusion is limited, 
reduced-RADPLAT appears to be an effective and feasible option for advanced-stage resectable 
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LEGENDS FOR FIGURES 
Fig. 1. Diagram of the clinical course of the 48 patients analyzed. CR, complete remission; PR, 
partial remission. CR/PR means that the primary site was CR and the regional site was PR. 
 
Fig. 2. Kaplan-Meier plots of overall survival (OS) (A) and progression-free survival (PFS) (B) for 
all patients. The estimated 3- and 5-year OS and PFS rates were 76.0 and 62.0%, and 58.0 and 
50.0%, respectively. 
 
Fig. 3. Kaplan-Meier plots of local control (LC) (A), locoregional control (LRC) (B), and 
laryngoesophageal dysfunction-free survival (LEDFS) (C) for all patients. Events for LEDFS 
include death, local relapse, total or partial laryngectomy, tracheotomy at 2 years or later, or feeding 
tube use at 2 years or later. The estimated 3- and 5-year LC, LRC, and LEDFS rates were 72.0 and 
70.0%, 66.0 and 62.0%, and 56.0 and 54.0%, respectively. 
Table 1. Baseline characteristics of patients












Pyriform sinus 35 (70.0)
Postcricoid 4 (8.0)



















Factor Level (n) HR 95% CI p -value HR 95% CI p -value
Age ≦65 (26) 1 0.428-2.602 0.907
≧66 (24) 1.055
Sex Male (39) 1 0.602-1.670 0.991
Female (11) 1.003
T-status T1-3 (30) 1 1.054-2.560 0.028 1 1.057-2.611 0.023
T4 (20) 1.645 1.675
N-status N0-1 (24) 1 0.794-1.946 0.343
N2-3 (26) 1.242
Stage II or III (16) 1 0.791-2.181 0.291
IV (34) 1.314
PS 0 (34) 1 0.575-2.128 0.204
1 or 2 (16) 1.346
Cisplatin dose (mg) <300 (16) 1 0.576-1.461 0.717
≧300 (34) 0.918
Number of infused
arteries ≦2 (25) 1 0.488-1.181 0.222
≧3 (25) 0.759
Laterality Unilateral (29) 1 0.624-3.617 0.363
Bilateral (21) 1.503
S-1 administration S-1 (+) (14) 1 1.002-4.331 0.049 1 1.024-4.431 0.043
S-1 (-) (36) 2.084 2.13
Univariate analysis Multivariate analysis
Table 2. Results of uni- and multivariate analyses of factors affecting overall survival
CI, confidence interval; HR, hazard ratio; PS, performance status; S-1 (+), patients with S-1 adjuvant chemotherapy;
S-1 (-), patients without S-1 adjuvant chemotherapy.
Factor Level (n) HR 95% CI p -value HR 95% CI p -value
Age ≦65 (26) 1 0.559-1.261 0.400
≧66 (24) 0.840
Sex Male (39) 1 0.595-1.596 0.917
Female (11) 0.974
T-status T1-3 (30) 1 1.063-2.398 0.024 1 1.046-2.364 0.030
T4 (20) 1.597 1.572
N-status N0-1 (24) 1 0.867-1.961 0.203
N2-3 (26) 1.304
Stage II or III (16) 1 0.861-2.176 0.184
IV (34) 1.369
PS 0 (34) 1 0.767-1.754 0.483
1 or 2 (16) 1.160
Cisplatin dose (mg) <300 (16) 1 0.763-1.852 0.444
≧300 (34) 1.189
Number of infused
arteries ≦2 (25) 1 0.857-1.938 0.223
≧3 (25) 1.289
Laterality Unilateral (29) 1 0.589-2.941 0.503
Bilateral (21) 1.316
S-1 administration S-1 (+) (14) 1 1.032-0.039 0.039 1 1.016-3.426 0.044
S-1 (-) (36) 1.894 1.865
Table 3. Results of uni- and multivariate analyses of factors affecting progression-free survival
Univariate analysis Multivariate analysis
S-1 (-), patients without S-1 adjuvant chemotherapy.
CI, confidence interval; HR, hazard ratio; PS, performance status; S-1 (+), patients with S-1 adjuvant chemotherapy;
Factor Level (n) HR 95% CI p -value HR 95% CI p -value
Age ≦65 (26) 1 0.523-1.656 0.226
≧66 (24) 0.781
Sex Male (39) 1 0.563-1.504 0.740
Female (11) 0.920
T-status T1-3 (30) 1 1.203-2.688 0.004 1 0.825-1.287 0.002
T4 (20) 1.796 1.934
N-status N0-1 (24) 1 0.811-1.789 0.356
N2-3 (26) 1.205
Stage II or III (16) 1 0.902-2.265 0.129
IV (34) 1.429
PS 0 (34) 1 0.717-1.626 0.714
1 or 2 (16) 1.080
Cisplatin dose (mg) <300 (16) 1 0.694-1.613 0.792
≧300 (34) 1.058
Number of infused
arteries ≦2 (25) 1 0.808-1.808 0.354
≧3 (25) 1.209
Laterality Unilateral (29) 1 0.772-3.729 0.188
Bilateral (21) 1.697
S-1 administration S-1 (+) (14) 1 1.126-3.773 0.019 1 1.212-4.100 0.010
S-1 (-) (36) 2.061 2.23
Univariate analysis Multivariate analysis
S-1 (-), patients without S-1 adjuvant chemotherapy.
Table 4. Results of uni- and multivariate analyses of factors affecting laryngo-esophageal dysfunction-free survival






Overall worst grade of
toxicity per patient 15 (30.0)
Table 5. Adverse events
Number of Grade 3
events (%)Events
No patient had Grade 4 or more severe toxicity.
Analyzed (50 patients) 
CR/PR (1 patient) 
Salvage surgery (1 patient): 
     Neck dissection (1 patient) 
Died of primary disease ( 1 patient) 
PR/CR or PR (5 patients) 
Salvage surgery (5 patients): 
     Total laryngopharyngectomy 
     + neck dissection (5 patients) 
Alive without evidence of disease 
( 3 patients) 
Died of primary disease (2 patient) 
CR/CR (44 patients) 
Recurrence (16 patients) 




Primary + Neck 
(2 patients) 
Distant site (5 patients): 
     Primary  + Neck 
     + Distant site (1 patient) 
     Distant site only (4 patients) 
Salvage surgery (2 patients): 
     Total laryngopharyngectomy 
     + neck dissection (2 patients) 
Salvage surgery (1 patient): 
     Neck dissection (1 patient) 
Alive with disease ( 2 patients) 
Died of primary disease (5 patients) 
Died of primary disease 
( 2 patients) 
Salvage surgery (1 patient): 
     Total laryngopharyngectomy 
     + Neck dissection (1 patient) 
Died of primary disease 
(1 patient) 
Died of other disease 
(1 patient) 
Salvage surgery (0 patients) 
Died of primary disease 
(5 patients) 
Alive without evidence of disease 
( 22 patients) 
Died of other disease (6 patients) 
No recurrence (28 patients) 
A 
B 
A 
B 
C 
